Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2000

View Archived Issues

Estrogen/progestin HRT may increase risk of breast cancer, according to NCI study

Siga Pharmaceuticals announces name change

Favorable long-term data reported for AstraZeneca's atypical antipsychotic

Boehringer Ingelheim cation channel blocker tested in rat focal ischemia

Cortex receives notice of allowance for sexual dysfunction patent

Hemopure significantly eliminates need for blood transfusion in vascular surgery

FDA grants Merck & Co. marketing exclusivity extension for Vasotec

Recently approved AmBisome label includes claim of superior safety compared to Abelcet

New GRF analogue from Theratechnologies shows promising phase Ib trial results

New study to evaluate FolateScan efficacy in detecting ovarian cancer

Acorda to commence phase II clinical trial of lead product for spinal cord injury

FDA clears small-molecule angiogenesis inhibitor for clinical testing

Positive phase III trial results reported by Genelabs for lupus treatment

MorphoSys achieves milestone in anticancer collaboration with GPC

Valentis highlights developments during second quarter

Ligand and Organon sign research agreement for progesterone receptor-modulating agents

Dura makes acquisition offer to Spiros, announces intentions regarding R&D

New gold complexes for X-ray therapy and imaging designed at Meiji Seika

Transmucosal clemastine under study at Nastech for motion sickness

Agents with nanomolar affinity for the MDR binding site jointly discovered by Japanese labs

German researchers disclose new agents for hypertension

Antiallergic agents from SB act as CCR3 receptor antagonists

Active Biotech reports on quinolines particularly useful in MS

New leader in regenerative medicine to result from three-way merger of Boston biotech companies

Anti-gpIIb/IIIa MAb fragment proves effective and safe in rat model of embolic stroke

Stroke news: DuPont gpIIb/IIIa antagonist shows promise in ischemic stroke

Study shows popular herbal supplement compromises the efficacy of anti-HIV drugs

Endonuclease activity as a potential therapeutic target for preventing neuronal apoptosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...